Fig. 2From: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology GroupClinical outcome in patients with high and low MEF2C expression in AAML0531. Estimates of the probability of OS (a), EFS (b), and RR (c) in patients with high (Q4) vs. low (Q1–3) relative MEF2C expressionBack to article page